Rocket Pharmaceuticals (RCKT) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Q3 2026 net loss narrowed to $49.2M from $50.3M; nine-month net income of $26.4M included a one-time $178.2M gain from the PRV sale.
Priorities included advancing Danon and cardiovascular gene therapy programs and preparing KRESLADI for launch; commercial readiness was achieved October 1, with two treatment centers ready for onboarding.
Financial highlights
Q3 operating expenses were $51.0M versus $52.2M a year earlier; R&D was $31.2M versus $34.1M and G&A was $19.8M versus $18.4M.
Nine-month operating expenses fell $41.4M year over year to $146.4M; R&D declined $20.5M to $92.1M and G&A declined $17.5M to $54.3M.
Q3 basic and diluted loss per share were $0.43 versus $0.45; nine-month diluted EPS was $0.23 versus a $1.63 loss.
September 30 cash, cash equivalents and investments totaled $279.4M, versus $188.9M at December 31, 2025; total assets were $419.5M and long-term debt was $30.4M.
Excluding the PRV-sale gain, operating activities used $124.1M cash in the first nine months; financing provided $34.2M and investing activities provided $107.8M.
Outlook and guidance
Current operating plan and available cash, investments, PRV proceeds and initial debt draw are expected to fund operations into Q3 2028; conditional additional borrowing could extend runway into 2029.
RP-A501 pivotal-study dosing is expected to finish by mid-2027, with topline 12-month results anticipated in mid-2028.
R&D spending is expected to remain significant and may rise as programs advance; KRESLADI is not expected to generate material near-term revenue given its ultra-rare population and phased rollout.
Latest events from Rocket Pharmaceuticals
- Pivotal RP-A501 targets 7 responders among 12, with dosing completion by mid-2027.RCKT
Status update - FDA clears pivotal Danon gene therapy trial; robust pipeline and cash runway support growth.RCKT
Morgan Stanley 24th Annual Global Healthcare Conference - Danon pivotal trial resumes at recalibrated dose with FDA alignment and strong safety profile.RCKT
Study update - Gene therapy pipeline advances with pivotal Danon trial, KRESLADI launch, and robust patient outreach.RCKT
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 net income hit $123.2M on PRV sale; FDA approval and strong cash support pipeline.RCKT
Q2 2026 - Early phase I data show RP-A601 improves cardiac function and arrhythmia burden at a safe dose.RCKT
Status Update - Cardiac gene therapy pipeline advances with pivotal trials and strong financial runway.RCKT
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Cardiac gene therapy pipeline advances with pivotal trials and major updates expected this year.RCKT
Jefferies Global Healthcare Conference 2026 - RP-A501 gene therapy achieved lasting cardiac and symptomatic improvements in Danon disease.RCKT
Study Update